前列地尔联合尿激酶治疗短暂性脑缺血发作的临床研究

Alprostadil combined with urokinase for treating transient ischemic attack

目的探讨前列地尔联合尿激酶治疗短暂性脑缺血发作(TIA)的疗效。方法选择住院治疗的TIA患者137例分为观察组85例,对照组52例。对照组患者给予常规治疗,观察组患者在常规治疗基础上应用前列地尔,治疗后观察2组患者的治疗有效率和血流速度。结果观察组患者治疗总有效率为85.9%,对照组为71.2%,2组比较差异有统计学意义(P<0.05)。治疗前2组患者患侧和健侧大脑前动脉(ACA)和大脑中动脉(MCA)血流速度比较差异均无统计学意义(P>0.05)。与治疗前比较,治疗后观察组患侧ACA及MCA的血流速度均增加,差异有统计学意义(P<0.01),健侧无明显改变(P>0.05)。对照组患者治疗后ACA、MCA的血流速度也有增加,但与治疗前比较差异均无统计学意义(P>0.05)。结论前列地尔能改善TIA患者病灶侧MCA和ACA的血流速度,联合尿激酶可以提高治疗TIA的总有效率。

Objective To investigate the effect of alprostadil combined with urokinase in the treatment of transient ischemic attack （TIA）. Methods One hundred and thirty-seven hospitalization patients with TIA were selected and divided into observation group（ n = 85 ） and control group（ n = 52）. The patients in control group were given conventional treatment; based on this, the patients in observation group were given alprostadil. The effective rate, speed of blood flow of the two groups were observed after treatment. Results The total effective rate of the observation group and control group was 85.9% and 71.2% respectively, there was statistic difference between the two groups （ P 〈 0.01 ）. Before treatment, there was no statistic difference of the speed of blood flow in affected side and uninjured side of the patients between the two groups（P 〉0.05）. Compared with before treatment, the speed of blood flow of anterior cerebral artery （ACA） and middle cerebral artery （MCA） in affected side of the observation group were increased after treatment, there were significant differences （P 〈 0. O1 ）. There was no statistic difference of the speed of blood flow of ACA and MCA in uninjured side of the patients in observation group before and after treatment（ P 〉 0.05 ）. There was no statistic difference of the speed of blood flow of ACA and MCA of the patients in control group before and after treatment （P 〉 0. 05 ）. Conclusion Alprostadil can improve the speed of blood flow in MCA and ACA. Alprostadil combined with urokinase can improve the total efficiency rate of the treatment of TIA.